Acurx Pharmaceuticals (ACXP) Scheduled to Post Quarterly Earnings on Wednesday

Acurx Pharmaceuticals (NASDAQ:ACXP) is scheduled to be posting its quarterly earnings results before the market opens on Wednesday, May 15th. Analysts expect Acurx Pharmaceuticals to post earnings of ($0.24) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Acurx Pharmaceuticals (NASDAQ:ACXP) last posted its earnings results on Friday, March 15th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.12). On average, analysts expect Acurx Pharmaceuticals to post $-1 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Acurx Pharmaceuticals Price Performance

Shares of NASDAQ:ACXP opened at $1.97 on Wednesday. Acurx Pharmaceuticals has a fifty-two week low of $1.17 and a fifty-two week high of $8.82. The firm’s 50 day simple moving average is $2.30 and its 200 day simple moving average is $3.26. The company has a market capitalization of $31.05 million, a price-to-earnings ratio of -1.77 and a beta of -1.79.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright cut their price objective on Acurx Pharmaceuticals from $14.00 to $12.00 and set a “buy” rating on the stock in a report on Tuesday, March 19th.

Acurx Pharmaceuticals Company Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.